<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214901</url>
  </required_header>
  <id_info>
    <org_study_id>1219.1</org_study_id>
    <nct_id>NCT02214901</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses BIBW 2948 BS (0.75 to 150 mg Inhalation Powder, Hard Capsule for HandiHaler®) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate safety, tolerability, and pharmacokinetics of BIBW 2948 BS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in vital signs (blood pressure, pulse rate, respiratory rate, orthostasis test, oral body temperature)</measure>
    <time_frame>Up to 8 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in clinical laboratory tests</measure>
    <time_frame>Up to 8 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Up to 8 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in airway resistance (Raw)</measure>
    <time_frame>Pre-dose, up to 24 hours after start of treatment</time_frame>
    <description>measured via plethysmography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator, a 4-point scale</measure>
    <time_frame>Up to 8 days after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analytes in plasma at different time points (AUCt1-t2)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of BIBW 3056 ZW in plasma (Cmax)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum concentration of the analytes in plasma (tmax)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of BIBW 3056 ZW eliminated in urine at different time points (Aet1-t2)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of BIBW 3065 ZW eliminated in urine at different time points (fet1-t2)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of BIBW 3056 ZW from 0 to 24 hours (CLR,0-24)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of BIBW 3056 ZW in plasma (λz)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life of BIBW 3056 ZW in plasma (t½)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of BIBW 3056 ZW in the body after inhalation (MRTih)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of BIBW 3056 ZW in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of BIBW 3056 ZW during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of the AUC 0-∞ that is obtained by extrapolation (%AUCtz-∞)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBW 2948 BS in single rising doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2948 BS for oral inhalation</intervention_name>
    <arm_group_label>BIBW 2948 BS in single rising doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males based on a complete medical history, including physical examination,
             vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests:

               -  No finding deviating from normal and of clinical relevance

               -  No evidence of a clinically relevant concomitant disease

          -  Aged between ≥21 and ≤50 years

          -  BMI (Body Mass Index) between ≥18.5 and ≤30 kg/m2

          -  Provision of written informed consent signed and dated prior to admission to the study
             in accordance with good clinical practice (GCP) and local legislation

        Exclusion Criteria:

          -  Any finding during the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to the drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (more than 60 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

